Risks and benefits of hormone therapy after menopause for cognitive decline and dementia: A conceptual review
The evidence and our beliefs about the beneficial or harmful effects of hormone therapy (HT) on brain aging have changed quite dramatically over time. In the last five years, several observational studies have shown an increased risk of dementia in women who had received HT [1 –5]. However, these results are opposite to the results of several observational studies and some clinical trials published over the last 30 years [6,7]. Therefore, in a 2022 editorial, we suggested that the answer to the simple question: “Is HT protective or harmful for cognitive decline and dementia?” is actually quite complex and may vary ...
Source: Maturitas - April 16, 2024 Category: Primary Care Authors: Walter A. Rocca, Kejal Kantarci, Stephanie S. Faubion Tags: Review article Source Type: research
Bacterial vaginosis after menopause: factors associated and women & #x2019;s experiences: a cross-sectional study of Australian postmenopausal women
Linde L. Stewart, Lenka A. Vodstrcil, Jacqueline Coombe, Catriona S. Bradshaw, Jane S. Hocking - Volume 21(3) Bacterial vaginosis is the most common cause of vaginal discharge in reproductive age women, yet little is known about it in postmenopausal women. This survey of Australian postmenopausal women found that women continue to report bacterial vaginosis after menopause, it affects their quality of life, and it is associated with sexual activity. Women of all ages are susceptible to bacterial vaginosis, research should not be limited to younger women, and developing an appropriate testing method should be a research pri...
Source: Sexual Health - April 16, 2024 Category: Sexual Medicine Authors: Linde L. Stewart Lenka A. Vodstrcil Jacqueline Coombe Catriona S. Bradshaw Jane S. Hocking Source Type: research
Serum Levels of Intercellular Adhesion Molecule 1 and Vascular Cell Adhesion Molecule 1 as Biomarkers to Predict Radiotherapy Sensitivity in Cervical Cancer
CONCLUSION: Serum ICAM-1 and VCAM-1 levels show potential as predictive biomarkers for radiotherapy sensitivity in cervical cancer.PMID:38618575 | PMC:PMC11006555 | DOI:10.1055/a-2275-0717 (Source: Geburtshilfe und Frauenheilkunde)
Source: Geburtshilfe und Frauenheilkunde - April 15, 2024 Category: OBGYN Authors: Lina Song Yali Gao Zhicong Wang Yufeng Shi Source Type: research
Oncology: What You May Have Missed in 2023
This article highlights important publications from 2023 on topics across a wide spectrum relating to the management of oncology patients. The literature was screened for significant new evidence that is relevant to internal medicine specialists and subspecialists whose focus is not oncology. Two articles address the importance of social interventions targeting end-of-life care for low-income and minority patients and the well-being of caregivers. Two additional articles address screening considerations in patients at risk for colorectal and lung cancer. Two more articles address safe use of hormone-related therapies to tr...
Source: Annals of Internal Medicine - April 15, 2024 Category: Internal Medicine Authors: Courtney H Coschi Lorin Dodbiba DuPont Guerry Source Type: research
Special Aspects of Cholesterol Metabolism in Women
CONCLUSION: Lowering high cholesterol levels, especially in postmenopausal women, may prevent the development of cardiovascular diseases.PMID:38616556 | DOI:10.3238/arztebl.m2024.0063 (Source: Deutsches Arzteblatt International)
Source: Deutsches Arzteblatt International - April 15, 2024 Category: General Medicine Authors: Ioanna Gouni-Berthold Ulrich Laufs Source Type: research
Experimental and new investigational drugs for the treatment of uterine fibroids
Expert Opin Investig Drugs. 2024 Apr 15. doi: 10.1080/13543784.2024.2343786. Online ahead of print.ABSTRACTINTRODUCTION: Uterine fibroids, the most prevalent benign tumors among reproductive-age women, pose treatment challenges that range from surgical interventions to medical therapies for symptom control. Progestins and estroprogestins effectively manage uterine bleeding by suppressing dysfunctional endometrium over fibroids. While GnRH agonists represent a crucial milestone in symptom treatment, their prolonged use results in menopausal-like symptoms and irreversible bone mineral density loss. Advancements in understand...
Source: Expert Opinion on Investigational Drugs - April 15, 2024 Category: Drugs & Pharmacology Authors: Giulio Evangelisti Simone Ferrero Umberto Perrone Claudio Gustavino Eugenio Volpi Alberto Izzotti Fabio Barra Source Type: research
Oncology: What You May Have Missed in 2023
This article highlights important publications from 2023 on topics across a wide spectrum relating to the management of oncology patients. The literature was screened for significant new evidence that is relevant to internal medicine specialists and subspecialists whose focus is not oncology. Two articles address the importance of social interventions targeting end-of-life care for low-income and minority patients and the well-being of caregivers. Two additional articles address screening considerations in patients at risk for colorectal and lung cancer. Two more articles address safe use of hormone-related therapies to tr...
Source: Cancer Control - April 15, 2024 Category: Cancer & Oncology Authors: Courtney H Coschi Lorin Dodbiba DuPont Guerry Source Type: research
Serum Levels of Intercellular Adhesion Molecule 1 and Vascular Cell Adhesion Molecule 1 as Biomarkers to Predict Radiotherapy Sensitivity in Cervical Cancer
CONCLUSION: Serum ICAM-1 and VCAM-1 levels show potential as predictive biomarkers for radiotherapy sensitivity in cervical cancer.PMID:38618575 | PMC:PMC11006555 | DOI:10.1055/a-2275-0717 (Source: Geburtshilfe und Frauenheilkunde)
Source: Geburtshilfe und Frauenheilkunde - April 15, 2024 Category: OBGYN Authors: Lina Song Yali Gao Zhicong Wang Yufeng Shi Source Type: research
Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis
Climacteric. 2024 Apr 15:1-10. doi: 10.1080/13697137.2024.2334083. Online ahead of print.ABSTRACTThis systematic review and meta-analysis investigated the efficacy and safety of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. PubMed, Cochrane Library, Embase and Web of Science were searched for randomized controlled trials (RCTs) published from inception to June 2023, comparing fezolinetant to placebo in postmenopausal women suffering from moderate-to-severe VMS. The mean difference and risk ratio were calculated for continuous and binary outcomes, respectively. R so...
Source: Climacteric - April 15, 2024 Category: Geriatrics Authors: Matheus Pedrotti Chavez Eric Pasqualotto Rafael Oliva Morgado Ferreira Alexandre Hohl Francisco Cezar Aquino de Moraes Pedro Henrique Siedschlag Schmidt Anna Lu íza Soares de Oliveira Rodrigues Joao Roberto de Sa Source Type: research
Oncology: What You May Have Missed in 2023
This article highlights important publications from 2023 on topics across a wide spectrum relating to the management of oncology patients. The literature was screened for significant new evidence that is relevant to internal medicine specialists and subspecialists whose focus is not oncology. Two articles address the importance of social interventions targeting end-of-life care for low-income and minority patients and the well-being of caregivers. Two additional articles address screening considerations in patients at risk for colorectal and lung cancer. Two more articles address safe use of hormone-related therapies to tr...
Source: Annals of Internal Medicine - April 15, 2024 Category: Internal Medicine Authors: Courtney H Coschi Lorin Dodbiba DuPont Guerry Source Type: research
Special Aspects of Cholesterol Metabolism in Women
CONCLUSION: Lowering high cholesterol levels, especially in postmenopausal women, may prevent the development of cardiovascular diseases.PMID:38616556 | DOI:10.3238/arztebl.m2024.0063 (Source: Deutsches Arzteblatt International)
Source: Deutsches Arzteblatt International - April 15, 2024 Category: General Medicine Authors: Ioanna Gouni-Berthold Ulrich Laufs Source Type: research
Experimental and new investigational drugs for the treatment of uterine fibroids
Expert Opin Investig Drugs. 2024 Apr 17:1-12. doi: 10.1080/13543784.2024.2343786. Online ahead of print.ABSTRACTINTRODUCTION: Uterine fibroids, the most prevalent benign tumors among reproductive-age women, pose treatment challenges that range from surgical interventions to medical therapies for symptom control. Progestins and estroprogestins effectively manage uterine bleeding by suppressing dysfunctional endometrium over fibroids. While GnRH agonists represent a crucial milestone in symptom treatment, their prolonged use results in menopausal-like symptoms and irreversible bone mineral density loss. Advancements in under...
Source: Expert Opinion on Investigational Drugs - April 15, 2024 Category: Drugs & Pharmacology Authors: Giulio Evangelisti Simone Ferrero Umberto Perrone Claudio Gustavino Eugenio Volpi Alberto Izzotti Fabio Barra Source Type: research
Serum Levels of Intercellular Adhesion Molecule 1 and Vascular Cell Adhesion Molecule 1 as Biomarkers to Predict Radiotherapy Sensitivity in Cervical Cancer
CONCLUSION: Serum ICAM-1 and VCAM-1 levels show potential as predictive biomarkers for radiotherapy sensitivity in cervical cancer.PMID:38618575 | PMC:PMC11006555 | DOI:10.1055/a-2275-0717 (Source: Geburtshilfe und Frauenheilkunde)
Source: Geburtshilfe und Frauenheilkunde - April 15, 2024 Category: OBGYN Authors: Lina Song Yali Gao Zhicong Wang Yufeng Shi Source Type: research
Fezolinetant for the treatment of vasomotor symptoms associated with menopause: a meta-analysis
Climacteric. 2024 Apr 15:1-10. doi: 10.1080/13697137.2024.2334083. Online ahead of print.ABSTRACTThis systematic review and meta-analysis investigated the efficacy and safety of fezolinetant for the treatment of moderate-to-severe vasomotor symptoms (VMS) associated with menopause. PubMed, Cochrane Library, Embase and Web of Science were searched for randomized controlled trials (RCTs) published from inception to June 2023, comparing fezolinetant to placebo in postmenopausal women suffering from moderate-to-severe VMS. The mean difference and risk ratio were calculated for continuous and binary outcomes, respectively. R so...
Source: Climacteric - April 15, 2024 Category: Geriatrics Authors: Matheus Pedrotti Chavez Eric Pasqualotto Rafael Oliva Morgado Ferreira Alexandre Hohl Francisco Cezar Aquino de Moraes Pedro Henrique Siedschlag Schmidt Anna Lu íza Soares de Oliveira Rodrigues Joao Roberto de Sa Source Type: research
Oncology: What You May Have Missed in 2023
This article highlights important publications from 2023 on topics across a wide spectrum relating to the management of oncology patients. The literature was screened for significant new evidence that is relevant to internal medicine specialists and subspecialists whose focus is not oncology. Two articles address the importance of social interventions targeting end-of-life care for low-income and minority patients and the well-being of caregivers. Two additional articles address screening considerations in patients at risk for colorectal and lung cancer. Two more articles address safe use of hormone-related therapies to tr...
Source: Annals of Internal Medicine - April 15, 2024 Category: Internal Medicine Authors: Courtney H Coschi Lorin Dodbiba DuPont Guerry Source Type: research
